country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-146444

Copy Link Print Information

Anticancer agent 56

Anticancer agent 56 (compound 4d) is a potent anti-cancer agent with agent-likeness properties, possessing anticancer activity against several cancer cell lines (IC₅₀<3 μM). Anticancer agent 56 induces cell cycle arrest at G2/M phase and triggers mitochondrial apoptosis pathway. Anticancer agent 56 acts by accumulation of ROS, up regulation of BAX, down regulation of Bcl-2 and activation of caspases 3, 7, 9.

For research use only. We do not sell to patients.

CAS No.: 2241915-59-1
Formula: C₂₀H₁₈ClN₃O₃
Molecular Weight:383.83

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (267 KB)

Anticancer agent 56 Chemical Structure

CAS No.: 2241915-59-1

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

IC₅₀: 0.64 ± 0.02 μM in Leukemia RPMI-8226, 0.96 ± 0.04 μM in Leukemia SR, 0.84 ± 0.07 μM in Leukemia K-562, 0.69 ± 0.01 μM in Melanoma M14, 0.24 ± 0.01 μM in Breast MCF7, 0.26 ± 0.01 μM in Colon HCT116, 2.95 ± 0.14 μM in Prostate PC3^[1]

All Bcl-2 Family Isoforms :

All Caspase Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
CCD-18Co	IC₅₀	17.15 μM Compound: 4d	Cytotoxicity against human CCD-18Co cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human CCD-18Co cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 31986406]
HCT-116	IC₅₀	0.26 μM Compound: 4d	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 31986406]
K562	IC₅₀	0.84 μM Compound: 4d	Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 31986406]
K562	IC₅₀	0.84 μM Compound: 14	Antiproliferative activity against human K562 cells Antiproliferative activity against human K562 cells	[PMID: 38889607]
Leukemia cell	IC₅₀	0.96 μM Compound: 14	Cytotoxicity against human Leukemia cancer cells Cytotoxicity against human Leukemia cancer cells	[PMID: 38889607]
M14	IC₅₀	0.69 μM Compound: 4d	Cytotoxicity against human M14 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human M14 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 31986406]
MCF-10A	IC₅₀	25 μM Compound: 4d	Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 31986406]
MCF7	IC₅₀	0.24 μM Compound: 4d	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 31986406]
PC-3	IC₅₀	2.95 μM Compound: 4d	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 31986406]
RPMI-8226	IC₅₀	0.64 μM Compound: 4d	Cytotoxicity against human RPMI-8226 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human RPMI-8226 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 31986406]
RPMI-8226	IC₅₀	0.64 μM Compound: 14	Antiproliferative activity against human RPMI-8226 cells Antiproliferative activity against human RPMI-8226 cells	[PMID: 38889607]
SR	IC₅₀	0.96 μM Compound: 4d	Cytotoxicity against human SR cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human SR cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 31986406]

Chemical Information

CAS No. 2241915-59-1
Molecular Weight 383.83
Formula C₂₀H₁₈ClN₃O₃
SMILES

COC1=C(C=C(C=C1)/C=C/C(C2=C(N(N=N2)C3=CC=C(C=C3)Cl)C)=O)OC
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (267 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Ashour HF, et al. 1,2,3-Triazole-Chalcone hybrids: Synthesis, in vitro cytotoxic activity and mechanistic investigation of apoptosis induction in multiple myeloma RPMI-8226. Eur J Med Chem. 2020;189:112062. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

100 mg

Get Quote In-stock

Amount: USD 0.00

Biological Activity
- Description
- IC₅₀ & Target
Chemical Information
Purity & Documentation
References

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Anticancer agent 56

All Bcl-2 Family Isoforms

All Caspase Isoforms

Biological Activity

Chemical Information

Purity & Documentation

References

Calculators

Help & FAQs

Anticancer agent 56 Related Classifications

HY-146444 Related Classifications